<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667082</url>
  </required_header>
  <id_info>
    <org_study_id>NPI-0052-103</org_study_id>
    <nct_id>NCT00667082</nct_id>
  </id_info>
  <brief_title>NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma</brief_title>
  <official_title>NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and
      efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat
      (Zolinza; a HDAC inhibitor) in patients with non-small cell lung cancer, pancreatic cancer,
      melanoma or lymphoma. Proteasome inhibitors block the breakdown of proteins by cells and HDAC
      inhibitors block modification of proteins regulating gene expression in cells. Both of these
      actions preferentially affect cancer cells, and the combination of the two has been seen to
      have a greater effect in laboratory studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat</measure>
    <time_frame>continuously</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics and pharmacodynamics of NPI-0052 and vorinostat</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and toxicity profile of the combination of NPI-0052 and vorinostat</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the anti-tumor activity of NPI-0052 and vorinostat</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>NPI-0052 + Vorinostat Dose-Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 dose-escalation cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPI-0052 (marizomib) + vorinostat</intervention_name>
    <description>NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle
Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle</description>
    <arm_group_label>NPI-0052 + Vorinostat Dose-Escalation</arm_group_label>
    <other_name>marizomib</other_name>
    <other_name>proteasome inhibitor</other_name>
    <other_name>HDAC inhibitor</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Karnofsky Performance Status (KPS) at 70% or more.

          2. Non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which
             a standard, approved therapy is not available. Patients must have lesions that are
             evaluable by RECIST criteria.

          3. All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have
             resolved to CTCAE (v. 3.0) Grade 1 or less(except for hemoglobin).

          4. Adequate bone marrow, renal, liver function.

          5. Signed informed consent.

        Exclusion Criteria:

          1. Recent administration of chemotherapy, biological, immunotherapy or investigational
             agent, major surgery, or radiotherapy.

          2. Intrathecal therapy.

          3. Known brain metastases.

          4. Significant cardiac disease.

          5. Prior treatment with vorinostat or NPI-0052, or other HDACi (including valproic acid)
             or proteasome inhibitors.

          6. Known allergy to any component of vorinostat. Prior hypersensitivity reaction of CTCAE
             Grade &gt; 3 to therapy containing propylene glycol or ethanol.

          7. Pregnant or breast-feeding women.

          8. Concurrent, active secondary malignancy for which the patient is receiving therapy.

          9. Significant active infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D Reich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Triphase Research and Development I Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital and University of Western Australia</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small Cell Lung Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

